Companies › Fertility Center of Las Vegas
1 active drug program in 1 registered trial: 1 Phase 4; Genitourinary; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| hCG injection human chorionic gonadotropin - luteal phase support | CGA, CGB | Phase 4 | Infertility (IVF Patients) | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07004192 | hCG injection | Phase 4 | Infertility (IVF Patients) | Genitourinary | Dec 2027 |
Zydus Lifesciences Granata Bio Dimerix Bioscience Chengdu Qingshan Likang Pharmaceutical Hope Medicine (Nanjing)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.